These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 6130560)

  • 1. The first clinical study of BW-234U in schizophrenia.
    Davidson J; Miller R; Wingfield M; Zung W; Dren AT
    Psychopharmacol Bull; 1982 Oct; 18(4):173-6. PubMed ID: 6130560
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of acute schizophrenia with sulforidazine].
    Sánchez E; Ning JL; Núñez H; Medina E
    Rev Neuropsiquiatr; 1975 Jun; 38(2):94-105. PubMed ID: 1839
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antipsychotic effects of caerulein on chronic schizophrenia].
    Moroharu T; Watanabe N; Ito M
    Seishin Shinkeigaku Zasshi; 1983; 85(9):611-5. PubMed ID: 6145173
    [No Abstract]   [Full Text] [Related]  

  • 4. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
    Chouinard G; Turnier L
    Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615
    [No Abstract]   [Full Text] [Related]  

  • 5. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
    Lieberman JA
    J Clin Psychiatry; 1996; 57 Suppl 11():68-71. PubMed ID: 8941173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinical characteristics and antipsychotic medication prescribing practices of first-episode schizophrenia in Israel: a naturalistic prospective study.
    Strous RD; Bar F; Keret N; Lapidus R; Kosov N; Chelben J; Kotler M
    Isr J Psychiatry Relat Sci; 2006; 43(1):2-9. PubMed ID: 16910378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of and decreasing of the dosage of risperidone in the treatment of schizophrenia. Global versus individual criteria.
    Gómez-Perretta C
    Actas Esp Psiquiatr; 2007; 35(1):77-8. PubMed ID: 17323229
    [No Abstract]   [Full Text] [Related]  

  • 10. Ethnic comparisons of antipsychotic use in schizophrenia.
    Wheeler A; Humberstone V; Robinson E
    Aust N Z J Psychiatry; 2008 Oct; 42(10):863-73. PubMed ID: 18777230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics study.
    Yoshimura R; Okamoto T; Nakamura J; Tateno M; Otsuka K; Takahashi H; Fujisawa D; Takamatsu T; Fujii S; Sato S; Inoue M; Sasaki H; Kuroki T; Shinfuku N
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):778-9. PubMed ID: 17109719
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of audit and feedback on antipsychotic prescribing in schizophrenia.
    Wheeler A; Humberstone V; Robinson E; Sheridan J; Joyce P
    J Eval Clin Pract; 2009 Jun; 15(3):441-50. PubMed ID: 19366393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIMH funds study of drugs for schizophrenia and Alzheimer's.
    J Psychosoc Nurs Ment Health Serv; 1999 Dec; 37(12):7. PubMed ID: 10618770
    [No Abstract]   [Full Text] [Related]  

  • 14. [FDA phase II and phase III drug evaluation of antipsychotic agents].
    Yagi K
    Seishin Shinkeigaku Zasshi; 1990; 92(9):584-92. PubMed ID: 1980369
    [No Abstract]   [Full Text] [Related]  

  • 15. [Zetidoline in the treatment of schizophrenia--initial experiences].
    Molcan J; Korínková V; Koníková M; Rakús A; Pribyl R
    Cesk Psychiatr; 1984 Jun; 80(3):143-5. PubMed ID: 6148151
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics.
    Kilian R; Dietrich S; Toumi M; Angermeyer MC
    Acta Psychiatr Scand; 2004 Aug; 110(2):108-18. PubMed ID: 15233711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of chronic hospitalized schizophrenics: diagnosis and treatment.
    Ban TA; Guy W; Wilson WH
    Psychiatr J Univ Ott; 1984 Dec; 9(4):191-5. PubMed ID: 6151202
    [No Abstract]   [Full Text] [Related]  

  • 18. [Initial experience with the neuroleptic Zetidoline in hospitalized schizophrenic patients].
    Zapletálek M; Libiger J; Tůma I
    Cesk Psychiatr; 1983 Apr; 79(2):83-8. PubMed ID: 6134590
    [No Abstract]   [Full Text] [Related]  

  • 19. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
    Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
    Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.